Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887952 | 0.90 | F2 (0.68) | F2 | |
| SCHEMBL3887943 | 0.88 | F2 (0.78) | F2 | |
| Hydrochloric Acid SCHEMBL3901218 | 0.88 | F2 (0.77) | F2 | |
| SCHEMBL13792151 | 0.84 | F2 (0.67) | F2 | |
| SCHEMBL8305968 | 0.84 | F2 (0.67) | F2 | |
| SCHEMBL3889095 | 0.83 | F2 (0.69) | F2 | |
| SCHEMBL3894857 | 0.83 | F2 (0.67) | F2 | |
| SCHEMBL3886861 | 0.80 | F2 (0.78) | F2 | |
| Hydrochloric Acid SCHEMBL3887821 | 0.79 | F2 (0.77) | F2 | |
| SCHEMBL3894408 | 0.78 | F2 (0.79) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-04-09 | — | — | US | disclosed |
| US-20180037569-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-02-08 | — | — | US | disclosed |
| EP-3262034-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | Palobiofarma, S.L. (ES) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135048-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2016-09-01 | — | — | WO | disclosed |
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-7550474-B2 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6288825-B1 | Electrochromic media for producing a preselected color and devices comprising same | GENTEX CORPORATION | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | ADORA2B, MTNR1A, ADORA3 | F2 3614/4885 |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | TFPI, F12, SPINT2 | F2 13/4885 |
| US-20180037569-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | ADORA2B, MTNR1A, ADORA3 | F2 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.